[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE


XML Print


Changzhou Cancer Hospital, Changzhou City, Jiangsu province, China , chengtao1216@hotmail.com
Abstract:   (197 Views)
Background: Globally, PD-1/PD-L1 inhibitors combined with bevacizumab have shown promising results in treating renal and lung cancers, but their efficacy in cervical cancer (CC) remains unclear. Superb microvascular imaging (SMI) is a novel technique for observing microcirculation in tumors. This study investigated the effectiveness and survival benefits of SMI in assessing tislelizumab combined with bevacizumab for treating CC. Materials and Methods: 86 patients with CC (2022–2023) were randomly divided into two groups: group A (bevacizumab, n=43) and group B (tislelizumab + bevacizumab, n=43). After 4 cycles of treatment, tumor volume and Adler blood-flow grades were assessed using color Doppler flow imaging (CDFI) and SMI. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value of both methods in assessing treatment effects. Results: Both CDFI and SMI demonstrated significant differences in treatment effectiveness between groups (p<0.05). CDFI showed improved Adler blood-flow grades after treatment in both groups (p<0.05), but they were not significantly different between the groups (P>0.05). SMI also revealed significant improvements (p<0.01) and greater differences between groups after treatment (p<0.05). The area under the curve (AUC) for SMI in evaluating therapeutic efficacy was 0.833 (sensitivity 86.05%, specificity 69.77%), while CDFI showed an AUC of 0.816 (sensitivity 79.07%, specificity 72.09%). Conclusions: Tislelizumab combined with bevacizumab significantly improves CC treatment. SMI outperforms CDFI in evaluating tumor microvessels and provides valuable insight for the planning of early CC treatment.
Full-Text [PDF 829 kb]   (52 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

International Journal of Radiation Research
Persian site map - English site map - Created in 0.03 seconds with 50 queries by YEKTAWEB 4718